The oncogenic effect of hepatitis C lasts beyond the disease's Eradication
ABSTRACT Hepatitis C virus (HCV) is widely prevalent worldwide, with an estimated 180 million people infected. Its manifestations are not limited to hepatic disease, as it has widely known immunomodulator and oncogenic effects. Most HCV associated autoimmune and lymphoproliferative diseases have been shown to subside after successful antiviral treatment. However, viral eradication doesn't always equal lymphoma cure. In some cases, the oncogenic effect lasts well beyond viral elimination. Although the new direct anti-viral agents (DAA) have proved to be safe and effective in treating HCV (with sustained viral responses of 91-95%), this treatment has inherent toxicities. Further, immunologic manifestations of HCV-associated diseases, when present, may require broad immunosuppression in association with the antiviral treatment. We present a case that illustrates the complexities of treating these viral mediated immunologic and lymphoproliferative diseases
Main Authors: | , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Portuguesa de Nefrologia
2019
|
Online Access: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000300007 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0872-01692019000300007 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0872-016920190003000072019-11-25The oncogenic effect of hepatitis C lasts beyond the disease's EradicationCerqueira,SofiaTeixeira,CatarinaAfonso,NunoCastro,RuiMorgado,TeresaAlves,Rui cryoglobulinemia hepatitis C virus lymphoma onconephrology ABSTRACT Hepatitis C virus (HCV) is widely prevalent worldwide, with an estimated 180 million people infected. Its manifestations are not limited to hepatic disease, as it has widely known immunomodulator and oncogenic effects. Most HCV associated autoimmune and lymphoproliferative diseases have been shown to subside after successful antiviral treatment. However, viral eradication doesn't always equal lymphoma cure. In some cases, the oncogenic effect lasts well beyond viral elimination. Although the new direct anti-viral agents (DAA) have proved to be safe and effective in treating HCV (with sustained viral responses of 91-95%), this treatment has inherent toxicities. Further, immunologic manifestations of HCV-associated diseases, when present, may require broad immunosuppression in association with the antiviral treatment. We present a case that illustrates the complexities of treating these viral mediated immunologic and lymphoproliferative diseasesinfo:eu-repo/semantics/openAccessSociedade Portuguesa de NefrologiaPortuguese Journal of Nephrology & Hypertension v.33 n.3 20192019-09-01info:eu-repo/semantics/reporttext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000300007en10.32932/pjnh.2019.10.037 |
institution |
SCIELO |
collection |
OJS |
country |
Portugal |
countrycode |
PT |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-pt |
tag |
revista |
region |
Europa del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Cerqueira,Sofia Teixeira,Catarina Afonso,Nuno Castro,Rui Morgado,Teresa Alves,Rui |
spellingShingle |
Cerqueira,Sofia Teixeira,Catarina Afonso,Nuno Castro,Rui Morgado,Teresa Alves,Rui The oncogenic effect of hepatitis C lasts beyond the disease's Eradication |
author_facet |
Cerqueira,Sofia Teixeira,Catarina Afonso,Nuno Castro,Rui Morgado,Teresa Alves,Rui |
author_sort |
Cerqueira,Sofia |
title |
The oncogenic effect of hepatitis C lasts beyond the disease's Eradication |
title_short |
The oncogenic effect of hepatitis C lasts beyond the disease's Eradication |
title_full |
The oncogenic effect of hepatitis C lasts beyond the disease's Eradication |
title_fullStr |
The oncogenic effect of hepatitis C lasts beyond the disease's Eradication |
title_full_unstemmed |
The oncogenic effect of hepatitis C lasts beyond the disease's Eradication |
title_sort |
oncogenic effect of hepatitis c lasts beyond the disease's eradication |
description |
ABSTRACT Hepatitis C virus (HCV) is widely prevalent worldwide, with an estimated 180 million people infected. Its manifestations are not limited to hepatic disease, as it has widely known immunomodulator and oncogenic effects. Most HCV associated autoimmune and lymphoproliferative diseases have been shown to subside after successful antiviral treatment. However, viral eradication doesn't always equal lymphoma cure. In some cases, the oncogenic effect lasts well beyond viral elimination. Although the new direct anti-viral agents (DAA) have proved to be safe and effective in treating HCV (with sustained viral responses of 91-95%), this treatment has inherent toxicities. Further, immunologic manifestations of HCV-associated diseases, when present, may require broad immunosuppression in association with the antiviral treatment. We present a case that illustrates the complexities of treating these viral mediated immunologic and lymphoproliferative diseases |
publisher |
Sociedade Portuguesa de Nefrologia |
publishDate |
2019 |
url |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000300007 |
work_keys_str_mv |
AT cerqueirasofia theoncogeniceffectofhepatitisclastsbeyondthediseaseseradication AT teixeiracatarina theoncogeniceffectofhepatitisclastsbeyondthediseaseseradication AT afonsonuno theoncogeniceffectofhepatitisclastsbeyondthediseaseseradication AT castrorui theoncogeniceffectofhepatitisclastsbeyondthediseaseseradication AT morgadoteresa theoncogeniceffectofhepatitisclastsbeyondthediseaseseradication AT alvesrui theoncogeniceffectofhepatitisclastsbeyondthediseaseseradication AT cerqueirasofia oncogeniceffectofhepatitisclastsbeyondthediseaseseradication AT teixeiracatarina oncogeniceffectofhepatitisclastsbeyondthediseaseseradication AT afonsonuno oncogeniceffectofhepatitisclastsbeyondthediseaseseradication AT castrorui oncogeniceffectofhepatitisclastsbeyondthediseaseseradication AT morgadoteresa oncogeniceffectofhepatitisclastsbeyondthediseaseseradication AT alvesrui oncogeniceffectofhepatitisclastsbeyondthediseaseseradication |
_version_ |
1756001698983182336 |